{"title":"人类和动物弯曲杆菌属菌株对抗菌剂耐药性的十年。","authors":"Rita Barata, Maria José Saavedra, Gonçalo Almeida","doi":"10.3390/antibiotics13090904","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives</b>: <i>Campylobacter</i> spp. remain a leading cause of bacterial gastroenteritis worldwide, with resistance to antibiotics posing significant challenges to treatment and public health. This study examines profiles in antimicrobial resistance (AMR) for <i>Campylobacter</i> isolates from human and animal sources over the past decade. <b>Methods</b>: We conducted a comprehensive review of resistance data from studies spanning ten years, analyzing profiles in resistance to key antibiotics, ciprofloxacin (CIP), tetracycline (TET), erythromycin (ERY), chloramphenicol (CHL), and gentamicin (GEN). Data were collated from various regions to assess global and regional patterns of resistance. <b>Results</b>: The analysis reveals a concerning trend of increasing resistance patterns, particularly to CIP and TET, across multiple regions. While resistance to CHL and GEN remains relatively low, the high prevalence of CIP resistance has significantly compromised treatment options for campylobacteriosis. Discrepancies in resistance patterns were observed between human and animal isolates, with variations across different continents and countries. Notably, resistance to ERY and CHL showed regional variability, reflecting potential differences in antimicrobial usage and management practices. <b>Conclusions</b>: The findings underscore the ongoing challenge of AMR in <i>Campylobacter</i>, highlighting the need for continued surveillance and research. The rising resistance prevalence, coupled with discrepancies in resistance patterns between human and animal isolates, emphasize the importance of a One Health approach to address AMR. Enhanced monitoring, novel treatment strategies, and global cooperation are crucial for mitigating the impact of resistance and ensuring the effective management of <i>Campylobacter</i>-related infections.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"13 9","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429304/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Decade of Antimicrobial Resistance in Human and Animal <i>Campylobacter</i> spp. Isolates.\",\"authors\":\"Rita Barata, Maria José Saavedra, Gonçalo Almeida\",\"doi\":\"10.3390/antibiotics13090904\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives</b>: <i>Campylobacter</i> spp. remain a leading cause of bacterial gastroenteritis worldwide, with resistance to antibiotics posing significant challenges to treatment and public health. This study examines profiles in antimicrobial resistance (AMR) for <i>Campylobacter</i> isolates from human and animal sources over the past decade. <b>Methods</b>: We conducted a comprehensive review of resistance data from studies spanning ten years, analyzing profiles in resistance to key antibiotics, ciprofloxacin (CIP), tetracycline (TET), erythromycin (ERY), chloramphenicol (CHL), and gentamicin (GEN). Data were collated from various regions to assess global and regional patterns of resistance. <b>Results</b>: The analysis reveals a concerning trend of increasing resistance patterns, particularly to CIP and TET, across multiple regions. While resistance to CHL and GEN remains relatively low, the high prevalence of CIP resistance has significantly compromised treatment options for campylobacteriosis. Discrepancies in resistance patterns were observed between human and animal isolates, with variations across different continents and countries. Notably, resistance to ERY and CHL showed regional variability, reflecting potential differences in antimicrobial usage and management practices. <b>Conclusions</b>: The findings underscore the ongoing challenge of AMR in <i>Campylobacter</i>, highlighting the need for continued surveillance and research. The rising resistance prevalence, coupled with discrepancies in resistance patterns between human and animal isolates, emphasize the importance of a One Health approach to address AMR. Enhanced monitoring, novel treatment strategies, and global cooperation are crucial for mitigating the impact of resistance and ensuring the effective management of <i>Campylobacter</i>-related infections.</p>\",\"PeriodicalId\":54246,\"journal\":{\"name\":\"Antibiotics-Basel\",\"volume\":\"13 9\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429304/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibiotics-Basel\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/antibiotics13090904\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics13090904","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
目的:弯曲杆菌属仍是全球细菌性肠胃炎的主要病因,其对抗生素的耐药性给治疗和公共卫生带来了巨大挑战。本研究探讨了过去十年中从人类和动物来源分离的弯曲杆菌的抗菌药耐药性(AMR)概况。方法:我们全面回顾了十年来的耐药性研究数据,分析了对主要抗生素环丙沙星 (CIP)、四环素 (TET)、红霉素 (ERY)、氯霉素 (CHL) 和庆大霉素 (GEN) 的耐药性概况。对来自不同地区的数据进行了整理,以评估全球和地区的抗药性模式。结果:分析表明,多个地区的耐药性呈上升趋势,尤其是对 CIP 和 TET 的耐药性。虽然对 CHL 和 GEN 的耐药性仍然相对较低,但对 CIP 的高耐药性已严重影响了弯曲杆菌病的治疗方案。人类和动物分离物之间的耐药性模式存在差异,不同大洲和国家之间也存在差异。值得注意的是,ERY 和 CHL 的耐药性表现出区域差异性,反映出抗菌药使用和管理方法的潜在差异。结论:研究结果凸显了弯曲菌 AMR 所带来的持续挑战,强调了持续监测和研究的必要性。耐药性流行率的上升,以及人类和动物分离物之间耐药性模式的差异,都强调了采用 "一体健康 "方法解决 AMR 问题的重要性。加强监测、新型治疗策略和全球合作对于减轻耐药性的影响和确保有效控制弯曲杆菌相关感染至关重要。
A Decade of Antimicrobial Resistance in Human and Animal Campylobacter spp. Isolates.
Objectives: Campylobacter spp. remain a leading cause of bacterial gastroenteritis worldwide, with resistance to antibiotics posing significant challenges to treatment and public health. This study examines profiles in antimicrobial resistance (AMR) for Campylobacter isolates from human and animal sources over the past decade. Methods: We conducted a comprehensive review of resistance data from studies spanning ten years, analyzing profiles in resistance to key antibiotics, ciprofloxacin (CIP), tetracycline (TET), erythromycin (ERY), chloramphenicol (CHL), and gentamicin (GEN). Data were collated from various regions to assess global and regional patterns of resistance. Results: The analysis reveals a concerning trend of increasing resistance patterns, particularly to CIP and TET, across multiple regions. While resistance to CHL and GEN remains relatively low, the high prevalence of CIP resistance has significantly compromised treatment options for campylobacteriosis. Discrepancies in resistance patterns were observed between human and animal isolates, with variations across different continents and countries. Notably, resistance to ERY and CHL showed regional variability, reflecting potential differences in antimicrobial usage and management practices. Conclusions: The findings underscore the ongoing challenge of AMR in Campylobacter, highlighting the need for continued surveillance and research. The rising resistance prevalence, coupled with discrepancies in resistance patterns between human and animal isolates, emphasize the importance of a One Health approach to address AMR. Enhanced monitoring, novel treatment strategies, and global cooperation are crucial for mitigating the impact of resistance and ensuring the effective management of Campylobacter-related infections.
Antibiotics-BaselPharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
7.30
自引率
14.60%
发文量
1547
审稿时长
11 weeks
期刊介绍:
Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.